Catherine Benziger MD MPH FAHA FACC
@drbenzigerheart.bsky.social
200 followers 240 following 38 posts
Non-invasive Cardiologist | clinical trialist | medical director of heart & vascular research, Essentia Health | associate professor, UMN Med School | public health expert | lipids, hypertension, cardiometabolic | runner, triathlete
Posts Media Videos Starter Packs
drbenzigerheart.bsky.social
Congratulations to the WARRIOR investigators and patients who participated! ✅High risk patients - 1 in 6 readmitted
✅Need to understand mechanisms in INOCA
✅Hard to enroll, hard to retain, underpowered neutral trial
#ACC25 @accintouch.bsky.social
drbenzigerheart.bsky.social
Julia Harris: Etiology of cardiac arrest in popular film and treatment is misleading and doesn't follow guidelines.
#ACC25 @accintouch.bsky.social
Reposted by Catherine Benziger MD MPH FAHA FACC
vietheartpa.bsky.social
Standing room only. Amazing debate on screening: CAC and separately Lpa, are we here for Universal screening?

don’t stop believing 🔥❤️❤️‍🔥
#CAC #knowlpa #knowfh #coronarydisease @accintouch.bsky.social @drbenzigerheart.bsky.social #physicianassociate #pasgobeyond #patientshealthfirst #pasdothat
Reposted by Catherine Benziger MD MPH FAHA FACC
erictopol.bsky.social
The use of an SGLT2 inhibitor drug improved outcomes in patients undergoing TAVI (transcatheter aortic valve implantation). A randomized, placebo-controilled trial of 620 patients with high risk
www.nejm.org/doi/full/10....
#ACC25 @nejm.org
Reposted by Catherine Benziger MD MPH FAHA FACC
drmarthagulati.bsky.social
Dr. Nissen presents #ALPACA assessing siRNA in ⬇️ Lp(a) Lepodisiran
♥️400 mg dose: 95% ⬇️, sustained 180 days but still effects after at 540 days
♥️ Large ⬇️ in Lp(a)
♥️ ApoB ⬇️ by 15%
♥️ safety favorable: 1 withdrew in placebo
#ACC25 #CVPrev
@nejm.org
📎 www.nejm.org/doi/full/10....
drbenzigerheart.bsky.social
Dr. Victor Dzau:
Future of #CVD care is going to be evolving rapidly over the next century:
❤️ Emphasis on prevention
❤️ Equitable access and affordable
❤️ Mission-based innovation
❤️ Develop national priorities

Need governance to oversee innovation, ensure ethics

#acc25
@accintouch.bsky.social
drbenzigerheart.bsky.social
Dr. Victor Dzau:
How do we improve #cvd with rising #obesity?
✅Start with 1° and 2° #cvprev
✅Primordial prevention

@accintouch.bsky.social #acc25
Reposted by Catherine Benziger MD MPH FAHA FACC
drmarthagulati.bsky.social
#ACC25 #STRIDE examined Semaglutide in PAD #LBCT
👟function impairment is common in PAD with limited Tx
👟93% completed trial, 1/3 women,~ BMI 28, functionally limited (0.1/mile)
👟Sema 💉🆚UC in T2DM+symptoms PAD: walking distance ⤴️ by 13% out to 1 year🤯💥
drbenzigerheart.bsky.social
Dr. Amy Sarma:
Who needs monogenic genetic testing for #SCAD ?
✅Men
✅Aortic aneurysm
✅Family history
✅SCAD pt wanting pregnancy

Otherwise likely polygenic
@accintouch.bsky.social #acc25
#cvprev
drbenzigerheart.bsky.social
Hey ladies! Come to theater 1 now to hear about why we need more women leaders in clinical trials #acc25
@accintouch.bsky.social
drbenzigerheart.bsky.social
Is menopause a disease? No! It's part of aging and occurs in 1/2 the pop.
Vasomotor symptoms are real
✅assess #cvd risk across the lifespan
✅Need outcome studies of HRT and GLP1RA by risk
✅ask♀️about all risk factors including pregnancy and cardiometabolic risks
@accintouch.bsky.social #acc25
drbenzigerheart.bsky.social
Excited to see the results of WARRIOR study. It was a tremendous effort from so many sites (including Essentia where I was site PI) with so many women with INOCA. More to come! @accintouch.bsky.social #acc25 #cvd
ahascience.bsky.social
WARRIOR Results presented at #ACC25
WARRIOR Results presented at #ACC25
Reposted by Catherine Benziger MD MPH FAHA FACC
drmarthagulati.bsky.social
BHF #protecttavi
#ACC25 #LBCT
❓Does routine use of Sentinel in TAVI reduce stroke

💥PROTECT TAVI demonstrates NO difference in Tx vs Control group in Stroke rate: currently would not use this in routine clinical practice
@nejm.org

www.nejm.org/doi/full/10....
Reposted by Catherine Benziger MD MPH FAHA FACC
jaccjournals.bsky.social
In a late-breaking clinical trial, Dr. John Forrest from @yaleschoolofmed.bsky.social reports that low-risk patients with AS treated with #TAVR had similar rates of mortality and stroke at 5 years compared to those treated with surgery jacc.org/doi/10.1016/...

#JACC #ACC25 #vhdAS #SAVR #CardioSky
drbenzigerheart.bsky.social
Dr. Leslie Cho discusses menopause and hormone therapy and effects on #cvd #lipid
✅Statins work in women
✅Hormones work if low risk
❌ avoid in patients with #cvd, #obesity, prior #vte
@accintouch.bsky.social #acc25
drbenzigerheart.bsky.social
Excited to be one of 71 sites in the WARRIOR study, results presented by Eileen Handberg @accintouch.bsky.social #acc25
✅ 17% event rate over 5 years
✅ No significant difference between intensive medical therapy and usually care
drbenzigerheart.bsky.social
Great start to #acc25 with the @accintouch.bsky.social 75th anniversary gala at the Field
drbenzigerheart.bsky.social
Come to the lp(a) debate on Sunday morning 10am S403A!
Reposted by Catherine Benziger MD MPH FAHA FACC
Reposted by Catherine Benziger MD MPH FAHA FACC
brendonneuen.bsky.social
In people with T2D, effects of GLP1-RA on CV, kidney & mortality outcomes are consistent irrespective of SGLT2i

Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation

www.ahajournals.org/doi/10.1161/...
Reposted by Catherine Benziger MD MPH FAHA FACC
cardioobdoc.bsky.social
Assessing Accuracy of CVD Prediction Using Female-Specific Risk Factors in Women Aged 45-69 Yrs in UK Biobank Study

#CardioSky #MedSky #Circulation
@ahajournals.bsky.social @ahascience.bsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social
www.ahajournals.org/doi/10.1161/...
drbenzigerheart.bsky.social
Great discussion on the current state of #statin and #dementia in older adults research at the #Preventabletrial investigator meeting